Citations

Clear

1526 citation(s) found for "Sun, C".

GBA mutations in Parkinson disease: earlier death but similar neuropathological features
Adler, Charles H. , Beach, Thomas G. , Shill, H. A., Caviness, John N., Driver‐Dunckley, Erika, Patel, Amit , Sue, Lucia I., Jacobson, Sandra A. , Davis, Kathryn, Belden, Christine M. , Dugger, Brittany N. , Paciga, Sara A. , Winslow, Ashley R. , Hentz, Joseph G. , Adler, C H , Paciga, S A , Shill, Holly A. , Driver‐Dunckley, Erika , Sabbagh, Marwan Noel , Patel, A., Serrano, Geidy E. , Hirst, Warren D. , Dugger, Brittany N

Mayo Clinic

European Journal of Neurology | August 18, 2017 | Volume: 24 | Issue: 11 | Pages: 1363-1368

10.1111/ene.13395 | PMID 28834018 Get It

Background and purpose Mutations in the glucocerebrosidase ( GBA ) gene are known to be a risk factor for Parkinson's disease ( PD ). Data on clinicopathological correlation are limited. The purpose of this study was to determine the clinicopathological findings that might distinguish PD cases with and without mutations in the GBA gene. Methods Data from the Arizona Study of Aging and Neurodegenerative Disorders were used to identify autopsied PD cases that did or did not have a GBA gene mutation. Clinical and neuropathological data were compared. Results Twelve PD cases had a GBA mutation and 102 did not. The GBA mutation cases died younger (76 vs. 81 years of age) but there was no difference in disease duration or clinical examination findings. No neuropathological differences were found in total or regional semi‐quantitative scores for Lewy‐type synucleinopathy, senile plaques, neurofibrillary tangles, white matter rarefaction or cerebral amyloid angiopathy scores. Conclusions In longitudinally assessed, autopsied PD cases, those with GBA mutations had a younger age at death but there was no evidence for clinical or neuropathological differences compared to cases without GBA mutations. Due to the small GBA group size, small differences cannot be excluded.
IRF4 Modulates CD8+ T Cell Sensitivity to IL-2 Family Cytokines
Huang, Su, Shen, Yingjia, Pham, Duy , Jiang, Li , Wang, Zheng , Kaplan, Mark H. , Zhang, Guangjun , Kaplan, Mark H , Sun, Jie

Mayo Clinic

ImmunoHorizons | August 15, 2017 | Volume: 1 | Issue: 6 | Pages: 92-100

10.4049/immunohorizons.1700020 | PMID 29564420 Get It

Abstract IFN regulatory factor 4 (IRF4) is a key transcription factor that promotes effector CD8+ T cell differentiation and expansion. The roles of IRF4 in regulating the CD8+ T cell response to cytokines have not been explored. In this article, we show that IL-2 and IL-15 signaling and STAT5 activation regulate IRF4 expression in CD8+ T cells. Gene-expression profile analysis has also revealed that IRF4 is required for expression of the receptors of IL-2 family cytokines CD122 and CD127. We found that IRF4 binds directly to CD122 and CD127 gene loci, indicating that it may directly promote CD122 and CD127 gene transcription. As a consequence, IRF4-deficient CD8+ T cells show diminished sensitivity to IL-2, IL-15, and IL-7 treatment in vitro. Furthermore, we found that IRF4-deficient CD8+ T cells had lower expression of CD122 and CD127 in vivo during influenza virus infection. These data suggest that IRF4 regulates the sensitivity of CD8+ T cells to IL-2 family cytokines, which correlates with the diminished effector and memory CD8+ T cell responses in IRF4-deficient CD8+ T cells.
Assessment of advanced hepatic MR elastography methods for susceptibility artifact suppression in clinical patients
Wang, Jin , Glaser, Kevin J. , Zhang, Tianhui , Shan, Qungang , He, Bingjun , Yin, Meng , Dzyubak, Bogdan , Kugel, Jennifer L., Kruse, Scott A., Grimm, Roger C., Venkatesh, Sudhakar K. , Dzyubak, Bogdan , Venkatesh, Sudhakar K , Yin, Meng , Chen, Jun , Ehman, Richard L.

Mayo Clinic

Journal of Magnetic Resonance Imaging | August 12, 2017 | Volume: 47 | Issue: 4 | Pages: 976-987

10.1002/jmri.25818 | PMID 28801939 Get It

PurposeTo assess the success rate, image quality, and the ability to stage liver fibrosis of a standard 2D gradient‐recalled echo (GRE) and four different spin‐echo (SE) magnetic resonance elastography (MRE) sequences in patients with different liver iron concentrations.Materials and MethodsA total of 332 patients who underwent 3T MRE examinations that included liver fat and iron quantification were enrolled, including 136 patients with all five MRE techniques. Thirty‐four patients had biopsy results for fibrosis staging. The liver stiffness, region of interest area, image quality, and success rate of the five sequences were compared in 115/136 patients. The area under the receiver operating characteristic curves (AUCs) and the accuracies for diagnosing early‐stage fibrosis and advanced fibrosis were compared. The effect of BMI (body mass index), the R2* relaxation time, and fat fraction on the image quality and liver stiffness measurements were analyzed.ResultsThe success rates were significantly higher in the four SE sequences (99.1–100%) compared with GRE MRE (85.3%) (all P < 0.001). There were significant differences of the mean ROI area between every pair of sequences (all P < 0.0001). There were no significant differences in the AUC of the five MRE sequences for discriminating advanced fibrosis (10 P‐values ranging from 0.2410–0.9171). R2* had a significant effect on the success rate and image quality for the noniron 2D echo‐planar imaging (EPI), 3D EPI and 2D GRE (all P < 0.001) sequences. BMI had a significant effect on the iron 2D EPI (P = 0.0230) and iron 2D SE (P = 0.0040) sequences.ConclusionAll five techniques showed good diagnostic performance in staging liver fibrosis. The SE MRE sequences had higher success rates and better image quality than GRE MRE in 3T clinical hepatic imaging.Level of Evidence: 3Technical Efficacy: Stage 5J. Magn. Reson. Imaging 2018;47:976–987.
Big Data and Genome Editing Technology: A New Paradigm of Cardiovascular Genomics
Krittanawong, Chayakrit , Sun, Tao , Herzog, Eyal

Mayo Clinic

Current Cardiology Reviews | August 7, 2017 | Volume: 13 | Issue: 4 | Pages: No page available

10.2174/1573403x13666170804152432 | PMID 28782493 Get It

Comprehensive biomechanical analysis of three reconstruction techniques following total sacrectomy: an in vitro human cadaveric model
Macki, Mohamed, Ramos, Rafael De la Garza , Murgatroyd, Ashley A., Mullinix, Kenneth P., Cunningham, Bryan W. , McCutcheon, Brandon A., Bydon, Mohamad , Gokaslan, Ziya L. , Sun, Xiaolei , De la Garza Ramos, Rafael

Mayo Clinic

Journal of Neurosurgery: Spine | August 4, 2017 | Volume: 27 | Issue: 5 | Pages: 570-577

10.3171/2017.2.spine161128 | PMID 28777063 Get It

OBJECTIVEAggressive sacral tumors often require en bloc resection and lumbopelvic reconstruction. Instrumentation failure and pseudarthrosis remain a clinical concern to be addressed. The objective in this study was to compare the biomechanical stability of 3 distinct techniques for sacral reconstruction in vitro.METHODSIn a human cadaveric model study, 8 intact human lumbopelvic specimens (L2–pelvis) were tested for flexion-extension range of motion (ROM), lateral bending, and axial rotation with a custom-designed 6-df spine simulator as well as axial compression stiffness with the MTS 858 Bionix Test System. Biomechanical testing followed this sequence: 1) intact spine; 2) sacrectomy (no testing); 3) Model 1 (L3–5 transpedicular instrumentation plus spinal rods anchored to iliac screws); 4) Model 2 (addition of transiliac rod); and 5) Model 3 (removal of transiliac rod; addition of 2 spinal rods and 2 S-2 screws). Range of motion was measured at L4–5, L5–S1/cross-link, L5–right ilium, and L5–left ilium.RESULTSFlexion-extension ROM of the intact specimen at L4–5 (6.34° ± 2.57°) was significantly greater than in Model 1 (1.54° ± 0.94°), Model 2 (1.51° ± 1.01°), and Model 3 (0.72° ± 0.62°) (p < 0.001). Flexion-extension at both the L5–right ilium (2.95° ± 1.27°) and the L5–left ilium (2.87° ± 1.40°) for Model 3 was significantly less than the other 3 cohorts at the same level (p = 0.005 and p = 0.012, respectively). Compared with the intact condition, all 3 reconstruction groups statistically significantly decreased lateral bending ROM at all measured points. Axial rotation ROM at L4–5 for Model 1 (2.01° ± 1.39°), Model 2 (2.00° ± 1.52°), and Model 3 (1.15° ± 0.80°) was significantly lower than the intact condition (5.02° ± 2.90°) (p < 0.001). Moreover, axial rotation for the intact condition and Model 3 at L5–right ilium (2.64° ± 1.36° and 2.93° ± 1.68°, respectively) and L5–left ilium (2.58° ± 1.43° and 2.93° ± 1.71°, respectively) was significantly lower than for Model 1 and Model 2 at L5–right ilium (5.14° ± 2.48° and 4.95° ± 2.45°, respectively) (p = 0.036) and L5–left ilium (5.19° ± 2.34° and 4.99° ± 2.31°) (p = 0.022). Last, results of the axial compression testing at all measured points were not statistically different among reconstructions.CONCLUSIONSThe addition of a transverse bar in Model 2 offered no biomechanical advantage. Although the implementation of 4 iliac screws and 4 rods conferred a definitive kinematic advantage in Model 3, that model was associated with significantly restricted lumbopelvic ROM.
Abstract 1286: Targeted deep sequencing of colorectal tumor tissues to study associations of tumor subtypes with germline genetic, lifestyle, and environmental risk factors
Zaidi, Syed Hassan Ejaz , Sun, Wei , Huyghe, Jeroen R. , Grasso, Catherine S. , Connolly, Charles M. , French, Amy J. , Mu, Jasmine, Giannakis, Marios , Quist, Michael J., Brenner, Hermann , Campbell, Peter , Chang‐Claude, Jenny , Ferretti, Vincent , Fuchs, Charles, Gsur, Andrea , Harrison, Tabitha A. , Hoffmeister, Michael , Lee, Stephen , Lemire, Mathieu , Miller, Jessica K. , Pasternack, Danielle, Teney, Cherie, Timms, Lee E., Wheeler, David , Zubair, Niha, Garraway, Levi A. , Hsu, Li, Gallinger, Steven, Thibodeau, Stephen N. , Peters, Ulrike , Trinh, Quang M. , Shinbrot, Eve , Borozan, Ivan , Buchanan, Daniel D. , Campbell, Peter, Chan, Andrew Lung-Tat , Gunter, Marc J. , Huang, Wen‐Yi , Krzyzanowski, Paul M. , Mardis, Elaine R. , Newcomb, Polly A. , Stein, Lincoln , Yung, Christina K. , Ogino, Shuji , Hudson, Thomas J , Hoffmeister, Michael , Harrison, Tabitha A , Brenner, Hermann

Mayo Clinic

Cancer Research | July 31, 2017 | Volume: 77 | Issue: 13_Supplement | Pages: 1286-1286

10.1158/1538-7445.am2017-1286 Get It

Abstract The Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO) in collaboration with the Colorectal Cancer Family Registry (CCFR) aims to identify genetic variants and environmental risk factors that impact colorectal cancer (CRC). Over 30 studies from North America, Europe, and Australia participate in GECCO. These studies have collected clinical, epidemiological, and survival data, as well as blood and tumor biospecimens, for over 80,000 CRC cases and controls. The current study aims to conduct targeted deep sequencing of tumors and matching normal DNA to identify recurrent and novel somatic and germline variants in 4,200 CRC cases. To achieve this goal, an AmpliSeq targeted sequencing panel of 1.12 Mbp was constructed to sequence the coding regions of 190 significantly mutated genes identified from whole exome sequencing datasets generated by the Nurses’ Health Study and Health Professional’s Follow-up Study, and The Cancer Genome Atlas. The panel also covers coding regions of 15 genes with germline high penetrance mutations in CRC, 54 regions to detect CRC-related copy number alterations (CNAs), and microsatellite and homopolymer repeat regions to identify defective DNA mismatch repair. Primers were also included to detect Fusobacterium nucleatum DNA in tumor biopsies, as F. nucleatum is thought to promote CRC carcinogenesis. Sequencing of the DNA libraries on Illumina HiSeq 2500 produced a mean coverage of greater than 500X for tumor DNA and 100X for normal DNA, with &gt;85% of the bases covered at the target at 50x. So far, targeted sequencing of &gt;1,500 DNA samples from CRC tumors and normal tissues has identified recurrent and novel somatic mutations, germline genetic variants, and hypermutation status of the tumors due to defective DNA mismatch repair or pathogenic mutations in the POLE gene. Targeted sequencing has also allowed quantification of the F. nucleatum DNA in tumor biopsies; the results were validated by a multiplex QPCR assay. At the AACR annual meeting, we will present targeted sequencing results generated from the first two GECCO-participating studies (n=1,300 cases). These data will be valuable for future association testing of somatic mutations, CNAs, hypermutation status, and F. nucleatum with germline genetic variants, lifestyle, and environmental risk factors and survival. This large study will allow development of better strategies for diagnosis, treatment, and prevention of CRC. Citation Format: Syed H. Zaidi, Wei Sun, Jeroen Huyghe, Catherine S. Grasso, Quang Trinh, Charles Connolly, Amy French, Jasmine Mu, Marios Giannakis, Eve Shinbrot, Ivan Borozan, Michael J. Quist, Hermann Brenner, Daniel Buchanan, Peter Campbell, Andrew Chan, Jenny Chang-Claude, Vincent Ferretti, Charles Fuchs, Andrea Gsur, Marc Gunter, Tabitha Harrison, Michael Hoffmeister, Wen-Yi Huang, Paul Krzyzanowski, Stephen Lee, Mathieu Lemire, Jessica Miller, Danielle Pasternack, Cherie Teney, Elaine Mardis, Polly Newcomb, Lincoln Stein, Lee Timms, David Wheeler, Christina Yung, Niha Zubair, Levi Garraway, Shuji Ogino, Li Hsu, Steven Gallinger, Stephen Thibodeau, Thomas Hudson, Ulrike Peters. Targeted deep sequencing of colorectal tumor tissues to study associations of tumor subtypes with germline genetic, lifestyle, and environmental risk factors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 1286. doi:10.1158/1538-7445.AM2017-1286
NFATc2 enhances tumor-initiating phenotypes through the NFATc2/SOX2/ALDH axis in lung adenocarcinoma
Xiao, Zhijie , Wang, Si-Qi, Zhu, Yun , Gao, Xu-Yuan, Tin, Vicky Pui‐Chi, Qin, Jing , Wang, Junwen , Wong, Maria Pik , Xiao, Zhi-Jie , Wang, Jun-Wen, Wong, Maria Pik , Liu, Jing , Gao, Xu-Yuan, Wang, Junwen , Qin, Jing

Mayo Clinic

eLife | July 24, 2017 | Volume: 6 | Issue: No issue available | Pages: No page available

10.7554/elife.26733 | PMID 28737489 Get It

Tumor-initiating cells (TIC) are dynamic cancer cell subsets that display enhanced tumor functions and resilience to treatment but the mechanism of TIC induction or maintenance in lung cancer is not fully understood. In this study, we show the calcium pathway transcription factor NFATc2 is a novel regulator of lung TIC phenotypes, including tumorspheres, cell motility, tumorigenesis, as well as in vitro and in vivo responses to chemotherapy and targeted therapy. In human lung cancers, high NFATc2 expression predicted poor tumor differentiation, adverse recurrence-free and cancer-specific overall survivals. Mechanistic investigations identified NFATc2 response elements in the 3’ enhancer region of SOX2, and NFATc2/SOX2 coupling upregulates ALDH1A1 by binding to its 5’ enhancer. Through this axis, oxidative stress induced by cancer drug treatment is attenuated, leading to increased resistance in a mutation-independent manner. Targeting this axis provides a novel approach for the long-term treatment of lung cancer through TIC elimination.
Essential Tremor and Depression
Aslam, Sana , Zhang, Nan , Caviness, John N., Driver‐Dunckley, Erika , Mehta, Shyamal H. , Belden, Christine M. , Zamrini, Edward , Beach, Thomas G. , Shill, Holly A. , Driver-Dunckley, Erika, Adler, Charles H. , Sabbagh, Marwan Noel

Mayo Clinic

Movement Disorders Clinical Practice | July 18, 2017 | Volume: 4 | Issue: 6 | Pages: 838-842

10.1002/mdc3.12530 | PMID 29805986 Get It

AbstractIntroductionDepression and neuropsychiatric disorders in individuals with essential tremor (ET) are not well characterized in the literature.MethodsWe compared 104 ET subjects with 481 non‐ET controls involved in the Arizona Study of Aging and Neurodegenerative Disorders. An analysis of baseline depression scales and neuropsychiatric inventory (NPI) was done between the two groups. Additionally, comparisons were made within the ET group based on tremor severity, duration of tremor, and age of onset.ResultsThere were no significant differences between the ET and non‐ET groups. There were no significant differences in the ET group above and below the median tremor duration. Additionally, no differences were found in the ET group based on objective measures of tremor severity, age of onset, or those with subjectively distressing tremor compared with those without.ConclusionThere were no significant differences in depressive symptoms between ET and non‐ET groups. Furthermore, no correlation was found between depressive symptoms in ET groups based on tremor severity, duration, or age of onset.
Targeting MYC as a Therapeutic Intervention for Anaplastic Thyroid Cancer
Enomoto, Keisuke , Zhu, Xuguang , Park, Sun‐Mi , Zhao, Li , Qi, Jun , Copland, John A. , Cheng, Sheue-yann, Zhu, Yuelin Jack , Willingham, Mark C. , Meltzer, Paul S. , Cheng, Sheue-yann

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | July 6, 2017 | Volume: 102 | Issue: 7 | Pages: 2268-2280

10.1210/jc.2016-3771 | PMID 28368473 Get It

Abstract Context: Recent studies showed that transcription of the MYC gene is driven by the interaction of bromodomain and extraterminal domain (BET) proteins with acetylated histones on chromatin. JQ1, a potent inhibitor that effectively disrupts the interaction of BET proteins with acetylated histones, preferentially suppresses transcription of the MYC gene. We recently reported that JQ1 decreased thyroid tumor growth and improved survival in a mouse model of anaplastic thyroid cancer (ATC) by targeting MYC transcription. The role of MYC in human ATC and whether JQ1 can effectively target MYC as a treatment modality have not been elucidated. Objective: To understand the underlying molecular mechanisms of JQ1, we evaluated its efficacy in human ATC cell lines and xenograft models. Design: We determined the effects of JQ1 on proliferation and invasion in cell lines and xenograft tumors. We identified key regulators critical for JQ1-affected proliferation and invasion of tumor cells. Results: JQ1 markedly inhibited proliferation of four ATC cell lines by suppression of MYC and elevation of p21and p27 to decrease phosphorylated Rb and delay cell cycle progression from the G0/G1 phase to the S phase. JQ1 blocked cell invasion by attenuating epithelial-mesenchymal transition signals. These cell-based studies were further confirmed in xenograft studies in which the size and rate of tumor growth were inhibited by JQ1 via inhibition of p21-cyclin/cyclin-dependent kinase-Rb-E2F signaling. Conclusions: These results suggest targeting of the MYC protein could be a potential treatment modality for human ATC for which effective treatment options are limited.
Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States
Muffly, Lori , Pasquini, Marcelo C. , Martens, Michael J. , Brazauskas, Ruta , Zhu, Xiaochun , Adekola, Kehinde , Aljurf, Mahmoud , Ballen, Karen K. , Baron, Frédéric , Beitinjaneh, Amer , Cahn, Jean‐Yves, Carabasi, Mathew, Chen, Yi‐Bin , Ciurea, Stefan O. , Copelan, Edward A. , D’Souza, Anita , Edwards, John , Foran, James M. , Freytes, César O. , Fung, Henry C., Hashmi, Shahrukh K. , Hildebrandt, Gerhard , Ho, Vincent T. , Jakubowski, Ann A. , Luskin, Marlise R. , Martino, Rodrigo , Olin, Rebecca L. , Olsson, Richard F. , Pawarode, Attaphol , Peres, Edward, Rezvani, Andrew R. , Rizzieri, David A. , Schouten, Harry C. , Sabloff, Mitchell , Seftel, Matthew D. , Seo, Sachiko , Sorror, Mohamed L. , Wirk, Baldeep , Wood, William A. , Bajel, Ashish R. , Battiwalla, Minoo , Cahn, Jean‐Yves , Chhabra, Saurabh , Gale, Robert Peter , Giralt, Sergio , Lazarus, Hillard M. , Luskin, Marlise R , Maziarz, Richard Thomas , McCarthy, Philip L. , Nishihori, Taiga , Savani, Bipin N. , Szer, Jeff , Artz, Andrew , D'Souza, Anita , Olsson, Richard F , Martino, Rodrigo , Muffly, Lori , Sabloff, Mitchell , Martens, Michael J , Sorror, Mohamed , Wood, William A

Mayo Clinic

Blood | July 3, 2017 | Volume: 130 | Issue: 9 | Pages: 1156-1164

10.1182/blood-2017-03-772368 | PMID 28674027 Get It

Key Points Over the last decade, allogeneic HCT has been increasingly administered in the United States to adults aged 70 and older with hematologic malignancies. Allogeneic transplant outcomes were reasonable; high comorbidity and ablative conditioning regimens were associated with inferior outcomes.